{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease - Hope, Reality, and the Unknown Going Forward

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Select the appropriate interventions for patients who have early Alzheimer's disease.
  2. Recognize the potential and actual therapeutic action of lecanemab.
  3. Identify the reported adverse effects of lecanemab.

Learning Outcomes

Seventy-five percent of participants will demonstrate competency in clinical reasoning regarding the state of the science in understanding and treating Alzheimer?s disease, including a new drug that targets the disorder?s pathophysiology, by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $17.95


  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH
  • NM - BON 3.0 CH
  • SC - BON 1.5 CH
  • WV - BOERN 1.5 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.

Awarded Advanced Pharmacology Hours

Test Code: CNS0523
Published: May/Jun 2023
Expires: 6/6/2025
Required Passing Score: 8/10 (80%)
Authors: Patricia Anne O'Malley, PhD, APRN-CNS